KaloBios distancing itself from Martin Shkreli with new drug pricing model
In the wake of its relationship with Martin Shkreli, KaloBios' new CEO Cameron Durrant "wants to clean up the messy legacy and start afresh," he said.
Monoclonal antibody player KaloBios shutting down
The long-beleaguered monoclonal antibody developer KaloBios is finally winding down operations - after a constant stream of setbacks since its February 2013 IPO.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.